TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02340052
Drug: Pain treatment
Normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
DrugBank: Salix alba bark (DB14274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registration af actual analgesic treatment and outcomes
Study: NCT00201409
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
Study: NCT02045589
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 intravenous administration
Study: NCT04666389
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
Study: NCT01855828
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
Study: NCT01855828
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).
Study: NCT01855828
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
Study: NCT01855828
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Study: NCT01855828
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
Study: NCT01866098
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
Study: NCT02002286
Drug: Tripterygium Wilfordii Hook F extract (TwHF extract)
Normalized name: Tripterygium wilfordii whole extract
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
Study: NCT02002286
Drug: cART
Normalized name: CARTON
DrugBank: Carteolol (DB00521)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study: NCT02517463
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
Study: NCT01747746
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
Study: NCT01747746
Drug: Warfarin and Enoxaparin
Normalized name: enoxaparin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Historical Control
Study: NCT00497913
Drug: Botulinum Toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT04752059
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
Study: NCT03961659
Drug: Liraglutid
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT03961659
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT03961659
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT01689727
Drug: Technetium Tc 99m EC20
Normalized name: TECHNETIUM (Tc 99m)
DrugBank: Technetium Tc-99m (DB14227)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02022748
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
Study: NCT02022748
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
Study: NCT02022748
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
Study: NCT01793948
Drug: metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00072787
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00072787
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03035929
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of dexamethasone IV 4 mg will be administered.
Study: NCT02302989
Drug: Ranibizumab 0.5mg
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00478244
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
Study: NCT00478244
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day -5 through Day -3: 25 mg/m2 IV over 60 min.
Study: NCT01870440
Drug: Ozurdex Intravitreal Injection (0.7 mg)
Normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal Injection
Study: NCT04208958
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
Study: NCT04208958
Drug: Vancomycin Oral Capsule
Normalized name: vancomycin Oral Capsule
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin is an antibiotic used to treat or prevent infection.
Study: NCT02131350
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00359801
Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
Study: NCT00359801
Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study: NCT03456388
Drug: Ammoxetine Hydrochloride Enteric-coated Tablets
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
Study: NCT04214626
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles).
Study: NCT04214626
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04214626
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04214626
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04214626
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT00001526
Drug: Daclizumab (Zenapax)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00663026
Drug: bapineuzumab
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bapineuzumab subcutaneous injection once per week for 6 months
Study: NCT00663026
Drug: bapineuzumab
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bapineuzumab subcutaneous injection once per week for 6 months
Study: NCT03082144
Drug: MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
Study: NCT03082144
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
Study: NCT01056289
Drug: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg
Normalized name: desvenlafaxine succinate 50 MG
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study: NCT01056289
Drug: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
Normalized name: desvenlafaxine succinate 25 MG
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study: NCT01534169
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
Study: NCT00098358
Drug: Zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02487303
Drug: Acetaminophen Oral
Normalized name: acetaminophen Oral Film
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1 gram 3 doses over 24 hours
Study: NCT03165292
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
Study: NCT03165292
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1-3 Thiotepa
Study: NCT03928210
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
Study: NCT04400929
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
Study: NCT01775189
Drug: oxycodone weight-matched placebo
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: crushed lactose tablets (powder) x 1 dose
Study: NCT01775189
Drug: crushed oxycodone IR 30 mg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
Study: NCT03668392
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
Study: NCT04851392
Drug: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
Study: NCT04851392
Drug: Cannabis with THC without CBD
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with THC without CBD - inhaled and vaporised cannabis flower
Study: NCT04851392
Drug: Placebo cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cannabis, without THC and without CBD - inhaled and vaporised
Study: NCT02974712
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03624309
Drug: Anlotinib Plus Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT03624309
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (75mg/m2 IV d1)
Study: NCT00401609
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00401609
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401609
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401609
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00401609
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04414345
Drug: CNM-Au8
Normalized name: CNM-Au8
DrugBank: CNM-Au8 (DB17952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily
Study: NCT02268968
Drug: Lidocaine 2% Gel
Normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
Study: NCT01755767
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib tablets
Study: NCT04623086
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec injection
Study: NCT04623086
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine injection
Study: NCT04131738
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib may be taken without regard to food. It should be taken at the same time every day.
Study: NCT00551018
Drug: Vicriviroc
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 30 mg tablet QD
Study: NCT00551018
Drug: emtricitabine and tenofovir disoproxil fumarate
Normalized name: Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 200/300 combination tablet QD
Study: NCT01935518
Drug: Fasudil
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
Study: NCT00442871
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eltrombopag 50 mg oral
Study: NCT03288818
Drug: Mechlorethamine Hydrochloride Gel
Normalized name: mechlorethamine Topical Gel
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT04380090
Drug: Docusate Sodium
Normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
Study: NCT01014793
Drug: cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
Study: NCT00425373
Drug: Valsartan + amlodipine 40/2.5 mg
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily